Page last updated: 2024-12-05

tromethamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6503
CHEMBL ID1200391
CHEBI ID9754
SCHEMBL ID975
MeSH IDM0022030

Synonyms (254)

Synonym
aminotris(hydroxymethyl)methane
tris-steril
trisaminol
tham
methanamine,1,1-tris(hydroxymethyl)-
nsc-6365
wln: q1xz1q1q
pehanorm
tris(hydroxymethyl)methylamine
tris-amino
methylamine,1,1-tris(hydroxymethyl)-
tham-e
tris(hydroxymethyl)methanamine
tromethanmin
tris, free base
tromethane
trisamine
trizma
tris buffertris-hydroxymethyl-aminomethan
trispuffer
TRIS ,
1, 2-amino-2-(hydroxymethyl)-
aminotrimethylolmethane
trometamole
tris(hydroxymethyl)aminomethane
tris buffer
trisamin
tris amino
nsc6365
trimethylolaminomethane
addex-tham
2-(hydroxymethyl)-2-amino-1,3-propanediol
tris (buffering agent)
tutofusin tris
talatrol
2-amino-2-(hydroxymethyl)propane-1,3-diol
2-amino-2-methylol-1,3-propanediol
smr000059179
MLS000028643
NCIOPEN2_001720
NCIOPEN2_000263
1,1,1-tris(hydroxymethyl)methanamine
CHEBI:9754 ,
tris base
tris-base
nsc65434
nsc-65434
2-(hydroxymethyl)-2-amino-1, 3-propanediol
tro.meta.mole
methylamine, 1,1,1-tris(hydroxymethyl)-
tro.meta.mol
methanamine, 1, 1,1-tris(hydroxymethyl)-
OPREA1_677781
ai3-03948
tris-hydroxymethyl-aminomethan [german]
methanamine, 1,1,1-tris(hydroxymethyl)-
tromethamine [usan]
einecs 201-064-4
tris(hydroxymethyly)amino methane
nsc 6365
epa pesticide chemical code 083901
caswell no. 036
tris-hydroxymethylaminomethane
trometamolum [inn-latin]
tromethamolum
hsdb 3408
inchi=1/c4h11no3/c5-4(1-6,2-7)3-8/h6-8h,1-3,5h
1,3-propanediol, 2-amino-2-(hydroxymethyl)-
2-amino-2-(hydroxymethyl)-1,3-propanediol
77-86-1
trometamol
C07182
tromethamine
sigma 7-9(r), >=99% (titration), crystalline
trizma(r) base, bioxtra, ph 10.5-12.0 (1 m in h2o), >=99.9% (titration)
trizma(r) base, bioperformance certified, meets ep, usp testing specifications, cell culture tested, >=99.9% (titration)
tromethamine, meets usp testing specifications
trizma(r) base, >=99.9% (titration), crystalline
trizma(r) base, primary standard and buffer, >=99.9% (titration), crystalline
DB03754
NCGC00159412-03
1H4N
NCGC00159412-02
1GNG
tromethamine (usp)
tham (tn)
D00396
trometamol (jan/inn)
tris(hydroxymethyl)aminomethane, acs reagent, >=99.8%
tris(hydroxy-d-methyl)amino-d2-methane, 98 atom % d
tri(hydroxymethyl)aminomethane
STK379529
trizma(r) base, puriss. p.a., >=99.7% (t)
tris(hydroxymethyl)aminomethane, >=99%
trizma(r) base, bioultra, for molecular biology, >=99.8% (t)
A0321
T2516
CHEMBL1200391
AKOS000121321
NCGC00159412-04
NCGC00159412-05
BBL000011
tris-(hydroxymethyl)methylamine
tris(hydroxymethyl)-aminomethane
ec 201-064-4
tris-hydroxymethyl-aminomethan
023c2whx2v ,
trometamolum
trometamol [inn]
unii-023c2whx2v
tromethamine [usan:usp]
2-amino-2-hydroxymethyl-1,3-propanediol
M02623
dtxcid503723
cas-77-86-1
tox21_303167
dtxsid2023723 ,
NCGC00257164-01
tox21_201646
NCGC00259195-01
tox21_111645
S4176
FT-0611014
AM90366
tris-d11
207802-44-6
gtpl7328
BP-13394
trometamol [mart.]
trometamol [jan]
tromethamine component of tham-e
tromethamine [mi]
tromethamine [hsdb]
tromethamine [usp monograph]
tromethamine [ii]
tham-e component tromethamine
tromethamine [inci]
tromethamine [vandf]
trometamol [who-dd]
tromethamine [usp-rs]
trometamol [ep monograph]
tromethamine [orange book]
CCG-214012
SCHEMBL975
tox21_111645_1
2-amino-2-[hydroxymethyl]-1,3-propandiol
2-amino-2-(hydroxyl-methyl)propane-1,3-diol
tris hydroxymethyl aminomethane
tris-(hydroxymethyl)-aminomethane
trishydroxymethylmethylamine
trizma base
2-amino-2-(hydroxymethyl) propane-1,3-diol
tris(hydroxymethyl) aminomethane
tris-(hydroxymethyl)-amino-methane
trishydroxymethyl aminomethane
tris-hydroxymethyl-methylamine
tris-amine
tris (hydroxymethyl) methylamine
tris (hydroxymethyl)aminomethane
J-610076
W-104296
trigmo base
2-amino-2-hydroxymethylpropanediol
aminotri(hydroxymethyl)methane
tromethamin
triladyl
tris (hydroxymethyl)aminoethane
2-amino-2-methylol-propane-1,3-diol
AB00443859_04
AB00443859_03
tris-buffered saline (tbs, 10x) ph 8.0
tris-buffered saline (tbs, 10x, high salt) ph 7.4
tris-buffered saline (tbs, 10x) ph 7.4, for western blot
tris-buffered saline (tbs, 20x) ph 7.4
tris-buffered saline (tbs, 10x) ph 7.6
tris-buffered saline (tbs, 10x) ph 7.4
tris(hydroxymethyl)aminomethane, electrophoresis grade
mfcd00132476
tris(hydroxymethyl)aminomethane, molecular biology grade
tris(hydroxymethyl)aminomethane, ultrapure
mfcd00004679
F0001-1979
tris(hydroxymethyl)aminomethane acs grade
trizma(r) base, bioultra, >=99.8% (t)
trizma(r) base, >=99.0% (t)
trizma(r) base, certified reference material for titrimetry, certified by bam, according to iso 17025, >=99.5%
sr-01000944234
SR-01000944234-1
tris(hydroxymethyl)aminomethane, jis special grade, >=99.0%
trizma(r) base, puriss. p.a., buffer substance, >=99.5%
tromethamine, united states pharmacopeia (usp) reference standard
tris(hydroxymethyl)aminomethane, >=99.8%
trizma(r) base, tested according to ph.eur.
tris(hydroxymethyl)aminomethane, ultrapure grade, >=99.9%
HMS3652L05
2-amino-2-(hydroxymethyl)-1,3-propanediol;
tris-base, molecular biology grade
tris (hydroxymethyl) aminomethane
P17498
wp quat (strong anion exchanger)
abx (antibody exchanger)
tromethamine, pharmaceutical secondary standard; certified reference material
trizma(r) base, cell culture tested, >=99.9% (titration), crystalline
tris(hydroxymethyl)aminomethane, p.a., acs reagent, 99.8%
trizma(r) base, vetec(tm) reagent grade, >=99%
trometamol, european pharmacopoeia (ep) reference standard
tris(hydroxymethyl)aminomethane, acs reagent, 99.9%
trizma(r) base, anhydrous, free-flowing, redi-dri(tm), >=99.9%
tris acidimetric, nist(r) srm(r) 723e
126850-05-3
amino (nh2) narrow-pore media-normal phase
126850-06-4
126850-08-6
SW219208-1
CS-W018524
BCP05578
Q413961
CS-0201543
CS-0201544
trometamol(tris),for molecular biology
trometamol(tris), inverted exclamation marky99.5%
CS-0201542
trometamol(tris),proteomics grade
HY-D0227
136760-04-8
4-anilino-1-(2-hydroxyethylamino)anthracene-9,11-dione
.beta.-d-ribo-hexopyranose, 1,6-anhydro-3-deoxy-2-o-(1-methylethyl)-4-o-(phenylmethyl)-
bakerbond(tm) cyano (cn)
126850-03-1
STR03166
HMS3885H09
[tris(hydroxymethyl)aminomethane]
tris-buffer
2-amino-2-hydroxymethyl-propane-1
(tris(hydroxymethyl)aminomethane)
PB47623
EN300-21687
tromethamine (ii)
b05bb03
tromethamine (usan:usp)
tromethamine (usp monograph)
1,1,1-tris(hydroxymethyl)-methylamine
trometamol (ep monograph)
2-amino-2-(hydroxymethyl)-propane-1,3-diol
b05xx02
tromethamine (usp-rs)
trometamol (mart.)
trometamolo
trometamolum (inn-latin)
tris base solution
HY-D0227D
HY-D0227E
HY-D0227C
Z104509094

Research Excerpts

Overview

Tromethamine (tris) is a non-CO2-generating buffer that has been proposed for use during cardiopulmonary resuscitation.

ExcerptReferenceRelevance
"Tromethamine-E appears to be a more effective agent for cystine stone dissolution."( Percutaneous catheter dissolution of cystine calculi.
Dretler, SP; Newhouse, JH; Pfister, RC; Prien, EL, 1984
)
0.99
"Tromethamine (tris) is a non-CO2-generating buffer that has been proposed for use during cardiopulmonary resuscitation."( The effect of CO2 and non-CO2-generating buffers on cerebral acidosis after cardiac arrest: A 31P NMR study.
Appleton, TJ; Martin, GB; Nowak, RM; Paradis, NA; Rosenberg, JM; Walton, D; Welch, KM, 1989
)
1

Toxicity

ExcerptReferenceRelevance
" These results indicate that Tris in concentrations commonly used as a buffer in physiological salines can exert toxic effects on neuro-muscular transmission in smooth and cardiac muscle though not in skeletal muscle."( Adverse effects of tris hydrochloride, a commonly used buffer in physiological media.
Gillespie, JS; McKnight, AT, 1976
)
0.26
" Significantly fewer patients treated with ketorolac reported adverse events in comparison with those treated with meperidine (17% and 59%, respectively), which suggests that it possesses a better therapeutic index than meperidine."( Comparison of the efficacy and safety of ketorolac and meperidine in the relief of dental pain.
Angelocci, D; Bynum, L; Fox, K; Fricke, JR; McHugh, D; Yee, JP, 1992
)
0.28
" Ketorolac was well tolerated, with rates of adverse events generally lower than those of the opiate comparators."( Analgesic efficacy and safety of single-dose oral and intramuscular ketorolac tromethamine for postoperative pain.
Brown, CR; Bynum, LJ; Clarke, PJ; Dickie, G; Evans, SA; Moodie, JE; Smith, BA; Wild, VM, 1990
)
0.51
" Three patients (one on ketorolac, two on Doleron) withdrew because of adverse events (vomiting)."( Analgesic efficacy and safety comparison of ketorolac tromethamine and Doleron for the alleviation of orthopaedic post-operative pain.
Johansson, S; Josefsson, G; Lindstrand, A; Malstam, J; Stenstroem, A,
)
0.38
" 7 These data show that five of the most commonly used artificial buffers, to study muscles in vitro, exert adverse effects on contractility of arterial and venous smooth muscle."( Adverse effects of artificial buffers on contractile responses of arterial and venous smooth muscle.
Altura, BM; Altura, BT; Carella, A; Turlapaty, PD, 1980
)
0.26
"In order to clarify the mechanism of the adverse effects of dietary amaranth, trisodium 1-(4-sulfo-1-naphthylazo)-2-naphthyl-3,6 disulfonic acid, the effects of amaranth in vitro and in a jejunum perfusion in vivo on intestinal sucrase were investigated in rats."( Mechanisms of adverse effect of amaranth feeding in the rat.
Hasegawa, K; Imamura, H; Kimura, T; Yoshida, A, 1983
)
0.27
" The safety profile was also studied by recording all adverse events noted."( Single-blind comparative analgesic and safety study of single doses of intramuscularly administered ketorolac tromethamine and pethidine hydrochloride in patients with pain following orthopaedic surgery.
Chhatwal, V; Kumar, VP; Lai, FO; Pereira, BP; Satku, K, 1994
)
0.5
"The end points analyzed were adverse effects, duration of postoperative ileus, degree of pain control, length of hospitalization, and development of postoperative confusion as measured on serial MMSEs."( Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial.
Avecilla, CS; Berg, RL; Nitschke, LF; Schlösser, CT; Selthafner, JV; Wengert, TJ, 1996
)
0.29
"Only two patients, both in the PCA group, reported adverse effects; neither required a change in analgesia group."( Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial.
Avecilla, CS; Berg, RL; Nitschke, LF; Schlösser, CT; Selthafner, JV; Wengert, TJ, 1996
)
0.29
" Most patients should probably be managed with PCA narcotics, but the addition of ketorolac might reduce narcotic dose and resultant adverse effects."( Does patient-controlled analgesia achieve better control of pain and fewer adverse effects than intramuscular analgesia? A prospective randomized trial.
Avecilla, CS; Berg, RL; Nitschke, LF; Schlösser, CT; Selthafner, JV; Wengert, TJ, 1996
)
0.29
" No treatment-related adverse events were reported in the ketorolac group, and only one treatment-related adverse event was reported in the vehicle group."( Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Ketorolac Radial Keratotomy Study Group.
Yee, RW, 1998
)
0.55
"5% ophthalmic solution was significantly more effective than, and as safe as, vehicle in the treatment of postoperative pain associated with radial keratotomy."( Analgesic efficacy and safety of nonpreserved ketorolac tromethamine ophthalmic solution following radial keratotomy. Ketorolac Radial Keratotomy Study Group.
Yee, RW, 1998
)
0.55
" Patients treated with ketorolac experienced the same low rate of treatment-related adverse events as those treated with the vehicle and exhibited the same improvement in visual acuity and manifest refraction."( Efficacy and safety of nonpreserved ketorolac ophthalmic solution in postoperative ocular pain following radial keratotomy.
Abel, ML; Brint, SF; Cheetham, JK; DeGryse, R; Rosenthal, A; Thompson, VM, 1999
)
0.3
"5% ophthalmic solution was significantly more effective than, and as safe as, the vehicle in alleviating the postoperative pain associated with RK."( Efficacy and safety of nonpreserved ketorolac ophthalmic solution in postoperative ocular pain following radial keratotomy.
Abel, ML; Brint, SF; Cheetham, JK; DeGryse, R; Rosenthal, A; Thompson, VM, 1999
)
0.3
" No adverse events were reported, and there were no significant changes in intraocular pressure in either group."( Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery.
Jenkins, JE; Pendelton, RA; Simone, JN, 1999
)
0.56
" To ensure participant safety, biomicroscopy, ophthalmoscopy, intraocular pressure, adverse events, and preoperative and postoperative visual acuity and refractive error were also monitored."( Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery.
Cheetham, JK; Grosserode, R; Rosenthal, A; Stewart, R, 1999
)
0.3
"These results suggest that reactive oxygen metabolites can contribute significantly to the development of intestinal lesions, and that R(-)-ketoprofen present in racemic preparations can enhance the toxic intestinal effects of S (+)-enantiomer via modification of neutrophil migration and oxidative stress."( Intestinal toxicity of ketoprofen-trometamol vs its enantiomers in rat. Role of oxidative stress.
Cabré, F; de la Lastra, CA; Herrerías, JM; Martín, MJ; Mauleón, D; Motilva, V; Nieto, A, 2000
)
0.31
" Adverse gastrointestinal events were recorded more often in the Hemabate group."( A prospective randomised trial to compare the efficacy and safety of hemabate and syntometrine for the prevention of primary postpartum haemorrhage.
Gordon, H; Lamont, RF; Logue, M; Morgan, DJ, 2001
)
0.31
"Cell degeneration in Alzheimer's disease is mediated by a toxic mechanism that involves interaction of the AbetaP peptide with the plasma membrane of the target cell."( Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides.
Arispe, N; Doh, M, 2002
)
0.31
" Treatment- related adverse events were experienced by 16% of patients in the dexketoprofen trometamol group compared with 21."( Comparison of the efficacy and safety of intravenously administered dexketoprofen trometamol and ketoprofen in the management of pain after orthopaedic surgery: A multicentre, double-blind, randomised, parallel-group clinical trial.
Wagenitz, A; Zippel, H, 2006
)
0.33
" Adverse events (AEs) were recorded."( Postmarketing cohort study to assess the safety profile of oral dexketoprofen trometamol for mild to moderate acute pain treatment in primary care.
Carne, X; Rios, J; Torres, F, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"2 pH units, and if there are no toxic effects."( Critical evaluation and further development of methods for testing ecotoxicity at multiple pH using Daphnia magna and Pseudokirchneriella subcapitata.
Kusk, KO; Rendal, C; Trapp, S, 2012
)
0.38
" Studies showed that Cd, in a dose-dependent manner, induced toxic effects in IPRL models, and these effects were associated with aminotransferase activity and lipid peroxidation."( Protective effect of magnesium and selenium on cadmium toxicity in the isolated perfused rat liver system.
Ghaffarian-Bahraman, A; Ghazi-Khansari, M; Jafari, A; Shahroozian, I, 2014
)
0.4
" The work reveals the significant side effect of Tris on the interaction of Aβ with Cu(2+), which will greatly improve the quantitative investigation on Aβ-Cu(2+) interaction and be helpful for the in-depth understanding of the roles of Aβ and Cu(2+) in AD neuropathology."( Side Effect of Tris on the Interaction of Amyloid β-peptide with Cu(2+): Evidence for Tris-Aβ-Cu (2+) Ternary Complex Formation.
Bin, Y; Jiang, Z; Xiang, J, 2015
)
0.42
" The Panel concluded that tromethamine, aminomethyl propanediol, and aminoethyl propanediol are safe in cosmetics in the practices of use and concentration as given in this safety assessment."( Safety Assessment of Tromethamine, Aminomethyl Propanediol, and Aminoethyl Propanediol as Used in Cosmetics.
Becker, LC; Belsito, DV; Bergfeld, WF; Gill, LJ; Heldreth, B; Hill, RA; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.75
" Safety endpoints included treatment-emergent adverse events, vital signs, electrocardiograms, and laboratory parameters."( Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design.
Ding, Y; Gao, X; Li, C; Li, X; Sun, J; Wang, W; Wu, M; Zhang, H; Zhu, X, 2020
)
0.56
" Neither treatment-emergent adverse event frequency nor severity increased with increasing felbinac trometamol dose."( Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design.
Ding, Y; Gao, X; Li, C; Li, X; Sun, J; Wang, W; Wu, M; Zhang, H; Zhu, X, 2020
)
0.56
" The most common treatment-related adverse events (TRAEs) were skin toxicity (50%), diarrhea (33."( Safety, Efficacy, and Pharmacokinetics of Metatinib Tromethamine Tablet in Patients with Advanced Refractory Solid Tumors: A Phase I Clinical Trial.
Bi, F; Cheng, K; Li, XY; Liao, ZY; Qiu, M; Zheng, L; Zhou, YW, 2021
)
0.87

Pharmacokinetics

ExcerptReferenceRelevance
" The absorption of ketorolac is rapid, Cmax being attained between 20 to 60 min."( Clinical pharmacokinetics of ketorolac tromethamine.
Brocks, DR; Jamali, F, 1992
)
0.55
" Values of steady-state volume of distribution and plasma clearance were approximately two times higher than those in adults but values of elimination half-life were similar."( The pharmacokinetics of postoperative intravenous ketorolac tromethamine in children.
Maunuksela, EL; Olkkola, KT, 1991
)
0.52
" The elimination of ketorolac was decreased slightly in the elderly following both doses, as evidenced by a prolongation in half-life (4."( Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly.
Garg, DC; Jallad, NS; Martinez, JJ; Mroszczak, EJ; Weidler, DJ, 1990
)
0.52
" The rate of absorption of K and formation of PHK, as determined by Cmax and Tmax values, was significantly slower following the im doses."( Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine.
Bynum, L; Jung, D; Ling, TL; Mroszczak, EJ; Sevelius, H; Wu, A, 1989
)
0.49
" The drug exhibited three-compartment characteristics with long terminal half-life (13 hr)."( Pharmacokinetics of TRIS (hydroxymethyl-)aminomethane in the rabbit.
Brasch, H; Iven, H, 1981
)
0.26
"The relationship between the pharmacokinetic properties and the analgesic effect of ketorolac was evaluated with the pain-induced functional impairment model in the rat."( Relationship between pharmacokinetics and the analgesic effect of ketorolac in the rat.
Flores-Murrieta, FJ; Granados-Soto, V; Hong, E; López-Muñoz, FJ, 1995
)
0.29
" Pharmacokinetic parameters were derived from plasma samples collected after the first and last active doses."( Tolerability, central effects and pharmacokinetics of intravenous ketorolac tromethamine in volunteers.
Bullingham, R; Hooftman, L; Lloyd, J; Lucker, P; Mroszczak, E, 1994
)
0.52
" Dexketoprofen trometamol showed the most rapid absorption rate, with highest Cmax and shortest t(max) values, whereas dexketoprofen free acid had the slowest absorption rate, and ketoprofen had an intermediate absorption rate."( Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses.
Antonijoan, RM; Artigas, R; Barbanoj, MJ; García, ML; Gich, I; Mauleón, D; Moros, C; Tost, D, 1998
)
0.3
" The assay is selective, sensitive, and applicable to pharmacokinetic analysis."( Gas chromatographic analysis of fosfomycin in plasma for pharmacokinetic analysis.
Bell, RG; Webster, GK,
)
0.13
" The main pharmacokinetic parameters were determined by a noncompartmental approach."( Clinical pharmacokinetics of parenteral dexketoprofen trometamol in healthy subjects.
Artigas, R; Capriati, A; Crea, A; Muller, F; Paredes, I; Valles, J; Zapata, A, 2006
)
0.33
" Model-independent pharmacokinetic parameters were obtained."( Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function.
Artigas, R; Bertolotti, M; Capriati, A; Crea, A; Muller, F; Paredes, I; Valles, J, 2006
)
0.33
" Pharmacokinetic endpoints included exposure of subjects to felblinac and metabolites of the drug in plasma, urine, and feces."( Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design.
Ding, Y; Gao, X; Li, C; Li, X; Sun, J; Wang, W; Wu, M; Zhang, H; Zhu, X, 2020
)
0.56
" Maximum plasma concentration and area under the curve increased in a dose-dependent manner for felblinac and its metabolite, showing linear pharmacokinetic characteristics at single and multiple doses."( Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design.
Ding, Y; Gao, X; Li, C; Li, X; Sun, J; Wang, W; Wu, M; Zhang, H; Zhu, X, 2020
)
0.56

Compound-Compound Interactions

electroacupuncture combined with tropisetron could effectively relieve carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia.

ExcerptReferenceRelevance
"To evaluate the hemodynamic actions of epinephrine combined with different alkaline buffers during experimental, open-chest, cardiopulmonary resuscitation (CPR)."( Hemodynamic effects of epinephrine in combination with different alkaline buffers during experimental, open-chest, cardiopulmonary resuscitation.
Rubertsson, S; Wiklund, L, 1993
)
0.29
" Sodium bicarbonate combined with epinephrine tended to produce lower systemic blood pressure than other combinations."( Hemodynamic effects of epinephrine in combination with different alkaline buffers during experimental, open-chest, cardiopulmonary resuscitation.
Rubertsson, S; Wiklund, L, 1993
)
0.29
" This may be particularly the case when triptan therapy is combined with a nonsteroidal anti-inflammatory drug (NSAID)."( Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura.
Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Cortelli, P; Curone, M; D'Onofrio, F; Frediani, F; Omboni, S; Pezzola, D; Reggiardo, G; Sette, G; Tullo, V; Valguarnera, F; Zava, D, 2014
)
0.4
"We evaluated the efficacy of electroacupuncture combined with tropisetron in treating carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia."( Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.
Chang, Y; Qu, M; Wei, Q; Yang, Q; Yao, Z; Yu, L, 2021
)
1.07
"Our study suggested that electroacupuncture combined with tropisetron could effectively relieve carboprost tromethamine-induced nausea and vomiting during cesarean section under lumbar anesthesia."( Efficacy of Electroacupuncture Combined with Tropisetron in Treating Carboprost Tromethamine-Induced Nausea and Vomiting during Cesarean Section under Lumbar Anesthesia.
Chang, Y; Qu, M; Wei, Q; Yang, Q; Yao, Z; Yu, L, 2021
)
1.06
" Carboprost aminobutyriol combined with oxytocin may be beneficial to infant outcome and uterine involution after cesarean section."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
0.97
"To investigate the effects of carboprost tromethamine combined with oxytocin on infant outcome, postpartum hemorrhage, and uterine involution in parturients undergoing cesarean section."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
1.24
"Carboprost aminobutyriol combined with carbestatin can effectively prevent the occurrence of bleeding after cesarean section, improve uterine involution, and improve neonatal birth quality, which is worth popularizing."( Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.
Gong, X; Wu, X, 2022
)
0.97

Bioavailability

A single dose of fosfomycin tromethamine is well absorbed and produces a therapeutic concentration in the urine for one to three days. The study was designed to examine the effect of benzalkonium chloride/ethylenediaminetetraacetic acid (BAK/EDTA) on the ocular bioavailability of ketorolac.

ExcerptReferenceRelevance
" Its oral bioavailability is estimated to range from 80 to 100%."( Clinical pharmacokinetics of ketorolac tromethamine.
Brocks, DR; Jamali, F, 1992
)
0.55
" Ketorolac is well absorbed and has a rapid onset of action."( Ketorolac: a parenteral nonsteroidal antiinflammatory drug.
Resman-Targoff, BH, 1990
)
0.28
" The rate of absorption of K and formation of PHK, as determined by Cmax and Tmax values, was significantly slower following the im doses."( Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine.
Bynum, L; Jung, D; Ling, TL; Mroszczak, EJ; Sevelius, H; Wu, A, 1989
)
0.49
" The results confirm that fosfomycin trometamol allows high bioavailability of fosfomycin."( Relative bioavailability of fosfomycin and of trometamol after administration of single dose by oral route of fosfomycin trometamol in fasting conditions and after a meal.
Borgia, M; Lodola, E; Longo, A, 1989
)
0.28
"9 h, respectively) and the systemic bioavailability was essentially complete."( Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration.
Bynum, L; Jung, D; Mroszczak, E, 1988
)
0.56
"The bioavailability of ketorolac after administration of two oral formulations containing 10 mg of ketorolac tromethamine, Exodol and Dolac, to 12 healthy Mexican volunteers was compared."( Comparative bioavailability of two oral formulations of ketorolac tromethamine: Dolac and Exodol.
Castañeda-Hernández, G; Flores-Murrieta, FJ; Granados-Soto, V; Herrera, JE; Hong, E, 1994
)
0.74
" Ketorolac applied in this way had a bioavailability greater than 80%."( Nasal formulations of ketorolac tromethamine: technological evaluation--bioavailability and tolerability in rabbits.
Bottoni, G; Canali, S; Peano, S; Rivolta, R; Santus, G; Testa, B, 1993
)
0.57
"This study was designed to examine the effect of benzalkonium chloride/ethylenediaminetetraacetic acid (BAK/EDTA) on the ocular bioavailability (Focular) of ketorolac tromethamine after ocular instillation to normal and de-epithelialized corneas of rabbits both in vitro and in vivo."( Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits.
Madhu, C; Nguyen, TG; Rix, PJ; Shackleton, MJ; Tang-Liu, DD, 1996
)
0.72
" Its oral bioavailability is estimated to be 80%."( Microencapsulation of ketorolac tromethamine by means of a coacervation-phase separation technique induced by the addition of non-solvent.
Demirel, M; Genç, L; Güler, E; Hegazy, N,
)
0.41
"Recent reports have disagreed on whether the bioavailability of S(+)-ketoprofen is affected by the presence of R(-)-ketoprofen."( Bioavailability of S(+)-ketoprofen after oral administration of different mixtures of ketoprofen enantiomers to dogs.
Carganico, G; García, ML; López, S; Mauleón, D; Tost, D; Vilageliu, J, 1998
)
0.3
" In the first study, the relative bioavailability of a single oral capsule of dexketoprofen free acid 25 mg or dexketoprofen trometamol 25 mg (given as 37 mg of the trometamol salt) was compared to ketoprofen 50 mg in 18 healthy volunteers."( Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses.
Antonijoan, RM; Artigas, R; Barbanoj, MJ; García, ML; Gich, I; Mauleón, D; Moros, C; Tost, D, 1998
)
0.3
"This randomized three-way, crossover pharmacokinetic study was performed to determine whether food or an antacid alters the bioavailability of dexketoprofen trometamol."( The effect of food and an antacid on the bioavailability of dexketoprofen trometamol.
Artigas, R; Barbanoj, MJ; Casini, A; De Luca, M; Gich, I; Mauleón, D; McEwen, J; Tost, D, 1998
)
0.3
" A single dose of fosfomycin tromethamine is well absorbed and produces a therapeutic concentration in the urine for one to three days."( Fosfomycin tromethamine: single-dose treatment of acute cystitis.
Stein, GE,
)
0.81
"An efficient method for gas chromatographic analysis of fosfomycin in plasma was developed for preliminary investigations of the bioavailability in poultry of 3 commercial complexes of fosfomycin: a levorotatory Ca(-) salt, a racemic Ca(+/-) salt, and a tromethamine (THAM) salt."( Gas chromatographic analysis of fosfomycin in plasma for pharmacokinetic analysis.
Bell, RG; Webster, GK,
)
0.31
" One of the major challenges in the development of pharmaceuticals is their formulation with other materials to give them the desired bioavailability profile when administered into the body."( Tris lipidation: a chemically flexible technology for modifying the delivery of drugs and genes.
Cameron, F; Francis, C; Johnston, J; Lockett, T; Manthey, M; Moghaddam, M; Reilly, W; Smith, K; Wells, X; Whittaker, R; Yang, Q, 2000
)
0.31
" These findings confirm "reasonable" bioavailability and biocompatibility of calcined mesoporous silicas with mouse lung within at least 5-14 h of exposure time."( In vitro study and biocompatibility of calcined mesoporous silica microparticles in mouse lung.
Al-Hammadi, S; Al-Salam, S; Asefa, T; Balhaj, G; Biradar, AV; Souid, AK; Sudhadevi, M; Tariq, S, 2011
)
0.37
"The objectives of this study were to prepare a powdered self-emulsified (SEDDS) formulation of meloxicam and to compare its oral bioavailability against commercial Mobic tablets."( Powdered self-emulsified lipid formulations of meloxicam as solid dosage forms for oral administration.
Agarwal, V; Alayoubi, A; Nazzal, S; Siddiqui, A, 2013
)
0.39
" Its rapid absorption rate with higher maximum plasma concentrations and shorter time to maximum values suggest that this drug is a good option for acute migraine treatment."( Dexketoprofen trometamol in the acute treatment of migraine attack: a phase II, randomized, double-blind, crossover, placebo-controlled, dose optimization study.
Maggioni, F; Mainardi, F; Pezzola, D; Zanchin, G; Zava, D, 2014
)
0.4
" The decrease could potentially affect oral bioavailability of the drug; should the amount of solubilizer decrease enough to lead to precipitation of the active drug from the formulation."( Monitoring the chemical and physical stability for tromethamine excipient in a lipid based formulation by HPLC coupled with ELSD.
Mulcey, M; Qiu, F; Rodríguez, SA; Tamblyn, T; Weigandt, K, 2015
)
0.67
"To enhance the oral bioavailability of asiatic acid tromethamine salt (AAS) by encapsulation in solid lipid nanoparticles (SLN)."( Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles.
Lingling, G; Weigen, L; Yuan, Z, 2016
)
0.9
"This study reveals that SLN is developed as a promising oral delivery system of AAS with significantly enhanced bioavailability and good storage stability."( Preparation, optimization, characterization and in vivo pharmacokinetic study of asiatic acid tromethamine salt-loaded solid lipid nanoparticles.
Lingling, G; Weigen, L; Yuan, Z, 2016
)
0.65
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The potassium salt of furazidine in dosage form with magnesium carbonate is preferred, since it is characterized by higher bioavailability and provides a therapeutic level of concentrations in urine above the MIC during the entire dosing period."( [Rationale for choosing an antibiotic for the treatment of cystitis: recommendations of clinical pharmacologists: A review].
Suvorova, MP; Yakovlev, SV, 2022
)
0.72

Dosage Studied

ExcerptRelevanceReference
" Both RU 31156 and DSCG inhibited anaphylactic bronchoconstriction in the rat, giving bell-shaped dose-response curves."( Inhibition of experimental immediate hypersensitivity reactions by a novel xanthone, RU 31156.
James, GW; Miller, P, 1978
)
0.26
" In the presence of Tris, agonist dose-response curves were shifted to the right, concomitant with a reduction in maximum tension in portal vein."( Influence of tris on contracile responses of isolated rat aorta and portal vein.
Altura, BM; Altura, BT; Turlapaty, PD, 1978
)
0.26
" During the 12 hours when most alkali therapy was given, babies dying with IVD received a mean total alkali dosage of 10-21 mmol/kg and those dying without IVH 6-34 mmol/kg (P less than 0-001)."( Hyaline membrane disease, alkali, and intraventricular haemorrhage.
Girling, DJ; Keith, IH; Slade, SA; Wigglesworth, JS, 1976
)
0.26
"04) superior to diflunisal in reducing the pain severity during the first 9 h of treatment; a difference possibly related to the more flexible dosage regimen of ketorolac."( Comparative multiple-dose study of ketorolac tromethamine and diflunisal for pain following orthopaedic surgery.
Fernández-Sabaté, A; Portabella, F,
)
0.39
" With the dosage regimens used, neither drug adequately controlled moderate to severe pain in the immediate postoperative period."( Intravenous ketorolac tromethamine versus morphine sulfate in the treatment of immediate postoperative pain.
Fragen, RJ; Peirce, RJ; Pemberton, DM, 1990
)
0.59
" The present results show that the elderly may need slightly less frequent dosing of ketorolac than young adults to maintain similar plasma levels."( Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly.
Garg, DC; Jallad, NS; Martinez, JJ; Mroszczak, EJ; Weidler, DJ, 1990
)
0.52
" Plasma and milk samples were collected on the two dosing days and on the first day after dosing."( The excretion of ketorolac tromethamine into breast milk after multiple oral dosing.
Bullingham, R; Lloyd, J; Manth, SM; Thompson, JS; Wischnik, A, 1989
)
0.57
" In the presence of Tris, the cumulative dose-response curve to norepinephrine was significantly shifted to the left, whereas methoxamine dose-response curves were similar in both buffers."( Tris buffer effects on melanophore aggregating responses.
Castrucci, AM; Visconti, MA, 1985
)
0.27
" Dose-response curves demonstrate that Tris significantly potentiates melanophore responses to noradrenalin doses between 10(-6) and 10(-5)M in this species."( Further assessment of a pharmacological effect of Tris buffer.
Burton, D, 1988
)
0.27
" coli that was fully resistant to fosfomycin in conventional minimum inhibitory concentration titrations responded to the highest dosage used, but this did not prevent further resistance from emerging."( Activity of the trometamol salt of fosfomycin in an in vitro model of the treatment of bacterial cystitis.
Greenwood, D,
)
0.13
" Our results suggested a positive dose-response relationship for ketorolac."( Ketorolac versus aspirin for postpartum uterine pain.
Barden, TP; Bloomfield, SS; Cissell, GB; Mitchell, J; Yee, JP,
)
0.13
" Analysis of allergen dose-response curve parameters shows that pretreatment with lodoxamide offers significant protection against experimental allergen-induced bronchoconstriction."( Protective effect opf lodoxamide tromethamine on allergen inhalation challenge.
Bewtra, AK; Bui, TC; Townley, RG; Watt, GD, 1980
)
0.54
" Treatment animals were then maintained on a regimen of intramuscular ketorolac using a three times a day dosing schedule for 14 days postoperatively."( Ketorolac (Toradol) and acute random-pattern skin flap survival in rat.
Cohen, JI; Cook, TA; Davis, RE; Robinson, JE; Urben, SL, 1995
)
0.29
" To determine the effects of withdrawal all subjects were then given further dosing with placebo (4 times daily) for 2 days while maintaining the double-blind nature of the previous drug assignment."( Tolerability, central effects and pharmacokinetics of intravenous ketorolac tromethamine in volunteers.
Bullingham, R; Hooftman, L; Lloyd, J; Lucker, P; Mroszczak, E, 1994
)
0.52
" The administered dosage was 10 mg every 6 h for ketorolac and 50 mg every 8 h for diclofenac sodium."( Ketorolac versus diclofenac sodium in cancer pain.
Corli, O; De Conno, F; Gallucci, M; Piva, L; Speranza, R; Tamburini, M; Toscani, F; Ventafridda, V, 1994
)
0.29
"Randomized, double-blind, placebo-controlled, dose-response evaluation."( Intravenous ketorolac as an adjunct to patient-controlled analgesia (PCA) for management of postgynecologic surgical pain.
Paige, D; Sevarino, FB; Silverman, DG; Sinatra, RS,
)
0.13
" In both tests KT had a poor analgesic effect without dose-response relationships."( Ketorolac tromethamine: an experimental study of its analgesic effects in the rat.
Bustamante, D; Paeile, C, 1993
)
0.69
" The authors conclude that THAM ameliorates the deleterious effect of prolonged hyperventilation, may be beneficial in ICP control, and warrants further study as to the dosage and timing of administration."( Effect of THAM upon outcome in severe head injury: a randomized prospective clinical trial.
Choi, S; Levi, L; Marmarou, A; Muizelaar, PJ; Rigamonti, D; Robinson, WL; Ward, JD; Wolf, AL; Young, H, 1993
)
0.29
" A dose-response relationship was evident between average daily ketorolac dose and both gastrointestinal bleeding and operative site bleeding (trend test P < ."( Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A postmarketing surveillance study.
Berlin, JA; Carson, JL; Feldman, H; Hennessy, S; Kimmel, S; Kinman, JL; Spitz, PW; Strom, BL, 1996
)
0.29
" Topical dosing led to relatively low aqueous and undetectable vitreous levels."( Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis.
Fiscella, RG; Rabiah, PK; Tessler, HH, 1996
)
0.29
" In the second protocol, dose-response curves were obtained using isolated (Langendorff) rat and rabbit (n = 6) hearts."( Beyond hyperkalemia: beta-blocker-induced cardiac arrest for normothermic cardiac operations.
Deslauriers, R; Ede, M; Gregorash, L; LeHouerou, D; Lessana, A; Pargaonkar, S; Salerno, TA; Summers, R; Ye, J, 1997
)
0.3
" In addition, the total daily dose of ketorolac was reduced following a change from intermittent bolus dosing to a continuous infusion."( Prolonged central intravenous ketorolac continuous infusion in a cancer patient with intractable bone pain.
Gordon, RL, 1998
)
0.3
" Groups of six rats received either vehicle or analgesic drug and antinociception was evaluated by evaluating the dose-response curves over time."( Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid.
Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998
)
0.3
"For each Mg concentration, the percentage recovery of aortic flow generated dose-response curves depending on Ca concentration."( Risk of low calcium and high magnesium in continuous warm hyperkalemic cardioplegia.
Kuroda, H; Mori, T; Nakamura, Y; Ohgi, S; Takemoto, N, 1999
)
0.3
" Prior to this study, the semen dose-response curve for each of the 4 bulls was developed in a field trial by freezing the semen and randomly distributing the straws throughout the Netherlands for insemination."( Fertility results using bovine semen cryopreserved with extenders based on egg yolk and soy bean extract.
den Daas, JH; Haring, RM; Kaal-Lansbergen, LM; van Wagtendonk-de Leeuw, AM, 2000
)
0.31
" Dexalgin was prescribed in dosage 75 mg daily during 5 days."( [Therapeutic effect of dexalgin on disturbances of vertebrogenic and nonvertebrogenic mechanisms in back pain].
Kryzhanovskiĭ, GN; Merkulov, IuA; Merkulova, DM, 2006
)
0.33
" This raised concerns over the stability and applied dosage in the in-house infusion preparations."( Method to determine stability and recovery of carboprost and misoprostol in infusion preparations.
Chu, KO; Pang, CP; Rogers, MS; Wang, CC, 2007
)
0.34
" Thus, the solubilizing power, dissolution-enhancing effect, and analgesic effect enhancer ability toward the drug make Tris particularly suitable for developing a reduced-dose, fast-release solid oral dosage form of nimesulide."( Comparison of the effect of tromethamine and polyvinylpyrrolidone on dissolution properties and analgesic effect of nimesulide.
Abdallah, OY; Abdelkader, H; Salem, HS, 2007
)
0.63
" Hypoglycaemia was treated by individually dosed infusion of 5% glucose in sterile water."( Six percent hydroxyethyl starch 130/0.4 impacts differently on blood glucose than 4% gelatine in a swine model of mixed acidaemia.
Boemke, W; Hiebl, B; Keckel, T; Koch, V; Russ, M; Unger, JK, 2009
)
0.35
" Dose-response curves for DEX and TRM, individually and combined in a 1 : 1 proportion based on their potency were obtained, and the doses that produced a 50% inhibition calculated."( Antinociceptive and anti-exudative synergism between dexketoprofen and tramadol in a model of inflammatory pain in mice.
Miranda, HF; Puig, MM; Romero, MA, 2012
)
0.38
" In responses to all three QT-lengthening compounds, RR, QT and QTc(F) lengthened similarly in a dose-response manner in both the failing and normal hearts."( Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts.
Hamlin, RL; Kijtawornrat, A; Sawangkoon, S, 2012
)
0.38
"Dexketoprofen has an antiepileptic feature and this effect increases as the dosage increases, however it is currently unknown through which mechanism this drug shows its anticonvulsant effect."( Inhibitor effect of dexketoprofen in rat model of pentylenetetrazol-induced seizures.
Aksoy, D; Erbaş, O; Solmaz, V, 2015
)
0.42
" SPF episodes at 24-h after early dosing were 25 % (Frova), 45 % (FroDex 25) and 41 % (FroDex 37."( Early (≤ 1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group stu
Allais, G; Barbanti, P; Benedetto, C; Bussone, G; Colombo, B; Comi, G; Cortelli, P; Curone, M; D'Arrigo, G; d'Onofrio, F; Frediani, F; Omboni, S; Sette, G; Tullo, V; Valguarnera, F, 2015
)
0.42
" The THAM dosage was calculated to normalize pH and exhibit a lasting effect."( THAM reduces CO2-associated increase in pulmonary vascular resistance - an experimental study in lung-injured piglets.
Ahlgren, KM; Borges, JB; Engström, J; Hedenstierna, G; Höstman, S; Larsson, A; Suarez-Sipmann, F, 2015
)
0.42
" From the second to the fifth day of treatment, if patient had VAS >40 mm, increased dosage to four times per day was allowed."( Double-blind, randomized, double-dummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain.
Amazonas, RB; Bocchi de Oliveira, MF; Ecclissato, Cda C; Plapler, PG; Scheinberg, MA, 2016
)
0.43
"The new system shows an improved pharmaceutical behavior and could be formulated in a dosage form to obtain a rapid and complete release of the drug available for absorption."( Multicomponent crystals of gliclazide and tromethamine: preparation, physico-chemical, and pharmaceutical characterization
Berbenni, V; Bruni, G; Castagna, F; Ferrara, C; Friuli, V; Girella, A; Maggi, L; Marini, A; Milanese, C; Mustarelli, P; Pardi, F, 2018
)
0.75
" Because DT has a short half-life, high and frequent dosing is used in treatment."( Treatment of oxidative stress-induced pain and inflammation with dexketoprofen trometamol loaded different molecular weight chitosan nanoparticles: Formulation, characterization and anti-inflammatory activity by using in vivo HET-CAM assay.
Kıyan, HT; Öztürk, AA, 2020
)
0.56
" Because radical production varies with many experimental parameters, hydroxyl radical dosimeters have been introduced to track the effective radical dosage experienced by the protein analyte."( Intrinsic Buffer Hydroxyl Radical Dosimetry Using Tris(hydroxymethyl)aminomethane.
Misra, SK; Riaz, M; Roush, AE; Sharp, JS; Weinberger, SR, 2020
)
0.56
" Dose-response curves were carried out for dexketoprofen, tapentadol, and dexketoprofen-tapentadol combinations in the acetic acid-induced writhing test in mice."( Antinociception and less gastric injury with the dexketoprofen-tapentadol combination in mice.
Alonso-Castro, ÁJ; Franco de la-Torre, L; Granados-Soto, V; Isiordia-Espinoza, MA; Partida-Castellanos, EM; Rivas-Carrillo, JD; Vidaurrazaga-Lugo, J; Zapata-Morales, JR, 2021
)
0.62
" The potassium salt of furazidine in dosage form with magnesium carbonate is preferred, since it is characterized by higher bioavailability and provides a therapeutic level of concentrations in urine above the MIC during the entire dosing period."( [Rationale for choosing an antibiotic for the treatment of cystitis: recommendations of clinical pharmacologists: A review].
Suvorova, MP; Yakovlev, SV, 2022
)
0.72
"5, 2, 4, 8, 12, and 24 hours after tooth extraction were counted by numeric rating scale(NRS), and the total dosage of emergent analgesic drugs used in 24 hours was recorded."( [Oral dexketoprofen tromethamine for preemptive analgesia in extraction of impacted teeth: a randomized controlled double-blind trial].
Hao, XH; Liu, N; Wu, XB; Zhao, J; Zhou, Y, 2023
)
1.23
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (10 Product(s))

Product Categories

Product CategoryProducts
Beauty & Personal Care10

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Earth Science Perfect Hydration Oil-Free Moisturizer Fragrance Free -- 2 fl ozEarth ScienceBeauty & Personal Careallantoin, chamomile, cetyl alcohol, tocopherol, panthenol, tocopherol, glyceryl stearate, glycerin, dimethicone, glyceryl laurate, phenoxyethanol, stearic acid, stearyl alcohol, tromethamine2024-11-29 10:47:42
NutriBiotic Face Creme -- 2 fl ozNutriBioticBeauty & Personal Careallantoin, vitamin C, benzyl alcohol, vitamin D3, tocopherol, dimethylaminoethanol, panthenol, ethylhexylglycerin, farnesol, tocopherol, vitamin E, glyceryl stearate, glycerin, glycerol monolaurate, phenoxyethanol, retinyl palmitate, squalene, stearic acid, stearyl alcohol, alpha lipoic acid, tocotrienol, tromethamine2024-11-29 10:47:42
Sukin Brightening Glow Night Moisturiser -- 1.69 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, cetearyl alcohol, cetyl alcohol, citric acid, tocopherol, tocopherol, glycerin, phenoxyethanol, sodium benzoate, squalane, tromethamine2024-11-29 10:47:42
Sukin Brightening Illuminating Moisturiser -- 2.03 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, cetearyl alcohol, citric acid, tocopherol, tocopherol, glycerin, phenoxyethanol, sodium benzoate, squalane, tromethamine2024-11-29 10:47:42
Sukin Deep Cleanse Purifying Tonic - Hair Care -- 4.23 fl ozSukinBeauty & Personal Carecitric acid, benzyl alcohol, citric acid, glycerin, glyceryl caprylate, sodium benzoate, sodium citrate, sodium cocoyl glutamate, sorbitol, tromethamine2024-11-29 10:47:42
The Seaweed Bath Co Calm Body Cream - Vetiver Geranium -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Caregeranium, allantoin, benzyl alcohol, carbomer, tocopherol, dehydroacetic acid, panthenol, tocopherol, glyceryl stearate, glycerin, vitamin B-5, stearic acid, stearyl alcohol, tromethamine, vanillin2024-11-29 10:47:42
The Seaweed Bath Co Energizing Body Cream - Grapefruit Orange -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Careorange, allantoin, ascorbic acid, benzyl alcohol, carbomer, tocopherol, dehydroacetic acid, panthenol, tocopherol, glyceryl stearate, glycerin, vitamin B5, stearic acid, stearyl alcohol, tromethamine2024-11-29 10:47:42
The Seaweed Bath Co Firming Body Cream - Orange Cedar -- 6 fl ozThe Seaweed Bath CoBeauty & Personal Careorange, phenyl ethyl acetate, allantoin, benzyl alcohol, carbomer, citronellol, tocopherol, gamma decalactone, dehydroacetic acid, panthenol, triethyl citrate, tocopherol, glyceryl stearate, glycerin, linalool, linalyl acetate, vitamin B-5, stearic acid, stearyl alcohol, tromethamine2024-11-29 10:47:42
The Seaweed Bath Co Firming Body Cream with chlorella & Green Coffee -- 1.5 fl ozThe Seaweed Bath CoBeauty & Personal Careallantoin, benzyl alcohol, carbomer, tocopherol, dehydroacetic acid, panthenol, triethyl citrate, tocopherol, vitamin E, glyceryl stearate, glycerin, vitamin B-5, stearic acid, stearyl alcohol, tromethamine2024-11-29 10:47:42
The Seaweed Bath Co Hydrate Body Cream - Unscented -- 1.5 fl ozThe Seaweed Bath CoBeauty & Personal Careallantoin, benzyl alcohol, carbomer, tocopherol, dehydroacetic acid, panthenol, tocopherol, vitamin E, glyceryl stearate, glycerin, vitamin B5, stearic acid, stearyl alcohol, tromethamine2024-11-29 10:47:42

Roles (1)

RoleDescription
bufferAny substance or mixture of substances that, in solution (typically aqueous), resists change in pH upon addition of small amounts of acid or base.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
triolA chemical compound containing three hydroxy groups.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency36.12540.007215.758889.3584AID624030
GLI family zinc finger 3Homo sapiens (human)Potency21.13170.000714.592883.7951AID1259369
farnesoid X nuclear receptorHomo sapiens (human)Potency54.87380.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency34.65610.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.84560.000229.305416,493.5996AID743075
DNA polymerase kappa isoform 1Homo sapiens (human)Potency26.67950.031622.3146100.0000AID588579
lamin isoform A-delta10Homo sapiens (human)Potency0.35480.891312.067628.1838AID1487
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CARBONIC ANHYDRASE IIHomo sapiens (human)Ki12.000012.000012.000012.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (96)

Assay IDTitleYearJournalArticle
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1091391Induction of Mn2+ complex loss in freshly lysed Spinacia oleracea (spinach) leaves chloroplasts assessed as chlorophyll a fluorescence at 0.8 M2008Journal of agricultural and food chemistry, Aug-27, Volume: 56, Issue:16
Biflavonoids isolated from Selaginella lepidophylla inhibit photosynthesis in spinach chloroplasts.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1091392Induction of loss of electron donation ability in freshly lysed Spinacia oleracea (spinach) leaves chloroplasts assessed as chlorophyll a fluorescence at 0.8 M2008Journal of agricultural and food chemistry, Aug-27, Volume: 56, Issue:16
Biflavonoids isolated from Selaginella lepidophylla inhibit photosynthesis in spinach chloroplasts.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1811Experimentally measured binding affinity data derived from PDB1997Biochemistry, Dec-16, Volume: 36, Issue:50
Histidine --> carboxamide ligand substitutions in the zinc binding site of carbonic anhydrase II alter metal coordination geometry but retain catalytic activity.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1997Biochemistry, Dec-16, Volume: 36, Issue:50
Histidine --> carboxamide ligand substitutions in the zinc binding site of carbonic anhydrase II alter metal coordination geometry but retain catalytic activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,431)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901882 (54.85)18.7374
1990's651 (18.97)18.2507
2000's411 (11.98)29.6817
2010's384 (11.19)24.3611
2020's103 (3.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.75 (24.57)
Research Supply Index8.28 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index154.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (83.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials284 (7.78%)5.53%
Reviews101 (2.77%)6.00%
Case Studies93 (2.55%)4.05%
Observational2 (0.05%)0.25%
Other3,171 (86.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]